Gilead Sciences Q1 FY26: where the revenue came from and where it went
The whole income statement of Gilead Sciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 7, 2026
Revenue$6.96B
+4% year over year
Gross profit$5.52B
79% margin
Operating profit$2.59B
37% margin
Net profit$2.02B
29% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 6.96 | 100% | +4% |
| Biktarvy | 3.36 | 48% | +7% |
| Other revenue | 1.27 | 18% | |
| Oncology product | 0.81 | 12% | |
| Trodelvy | 0.40 | 6% | +37% |
| Yescarta | 0.33 | 5% | −14% |
| Sofosbuvir velpatasvir | 0.28 | 4% | |
| Genvoya | 0.26 | 4% | −27% |
| Vemlidy | 0.24 | 3% | |
| Cost of revenue | −1.45 | 21% | |
| Gross profit | 5.52 | 79% margin | +2pp |
| SG&A | −1.45 | 21% | +2pp |
| Other | −1.48 | 21% | |
| Operating profit | 2.59 | 37% margin | +4pp |
| Tax | −0.57 | ||
| Net profit | 2.02 | 29% margin | +9pp |
347 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest